Revive Therapeutics Ltd. (RVV.CN)

0.0300 +0.0050 (+20.00%) At close: 01:23PM EDT

Revive Therapeutics Ltd.

The Canadian Venture Building
82 Richmond Street East
Toronto, ON M5C 1P1
Canada
888-901-0036
https://revivethera.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Michael Frank	Chairman & CEO	360k	N/A	1961
Mr. Carmelo Marrelli ACIS, B.Comm., C.A., CGA, CPA	Chief Financial Officer	130.11k	N/A	1971
Dr. Kelly T. McKee Jr., M.D., M.P.H.	Chief Scientific Officer Consultant	N/A	N/A	1951
Dr. Onesmo Mpanju Ph.D.	Chief Regulatory Affairs Consultant	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. The company is based in Toronto, Canada.

Corporate Governance

Revive Therapeutics Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.